Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...
Eli LIlly & Co. said Tuesday it is launching 7.5 and 10 milligram versions of its Zepbound single-dose vials at a price of $499-a-month for self-pay patients, down from $699 previously. The drug giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback